{"id":"W2168849655","doi":"10.2147/btt.s1832","title":"Erlotinib in the treatment of advanced pancreatic cancer","year":2008,"lang":"en","type":"article","venue":"Biologics","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Gemcitabine; Pancreatic cancer; Medicine; Oncology; Internal medicine; Erlotinib Hydrochloride; Malignancy; Epidermal growth factor receptor; Clinical trial; Cancer; Chemotherapy; EGFR inhibitors; Targeted therapy; Tyrosine-kinase inhibitor; Cabozantinib; Pharmacology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004581487,0.0002112378,0.0004719482,0.0004295705,0.000152787,0.0003628306,0.0001813991,0.0004099923,0.0009889266],"category_scores_gemma":[0.0003471966,0.00005759428,0.0001922567,0.0004570181,0.0001419863,0.0002356313,0.000171856,0.0008288054,0.000401279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004838675,"about_ca_system_score_gemma":0.000335977,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00070368,"about_ca_topic_score_gemma":0.001895111,"domain_scores_codex":[0.9998927,0.00003472907,0.00001209997,0.00001045498,0.00002911308,0.00002079844],"domain_scores_gemma":[0.9998939,0.00003042445,0.0000272477,0.000005012821,0.00001657537,0.00002677663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002325425,0.0004358886,0.002156356,0.000998505,0.000085816,0.002092602,0.00008065973,0.001185514,0.009261051,0.001798666,0.01455664,0.9650229],"study_design_scores_gemma":[0.005679546,0.01304865,0.0545171,0.001257746,0.0006011077,0.02755654,0.0002009946,0.003929504,0.02193582,0.00388229,0.8673077,0.00008299349],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.1647893,0.7901429,0.001087104,0.01080914,0.0008855452,0.00007047185,0.000219995,0.0001567411,0.03183883],"genre_scores_gemma":[0.6140482,0.3711097,0.001434561,0.00202134,0.001131204,0.00005335567,0.0003675234,0.00001491127,0.009819144],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0009889266,"threshold_uncertainty_score":0.003510714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1107101820081687,"score_gpt":0.3985478263578194,"score_spread":0.2878376443496507,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}